Insider Trading activities at Ionis Pharmaceuticals Inc (IONS) , Part 6

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ionis Pharmaceuticals Inc (IONS) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ionis Pharmaceuticals Inc. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 874015.

Total stock buying since 2015: $477,900.
Total stock sales since 2015: $220,707,715.
Total stock option exercises since 2015: $87,022,179.


27 insiders reported insider trading activities at Ionis Pharmaceuticals Inc (IONS):
Insider trading activities of Castleman Breaux
Insider trading activities of Devers Shannon L.
Insider trading activities of Reikes Peter N
Insider trading activities of Crooke Stanley T
Insider trading activities of Herman Joan E
Insider trading activities of O'neil Patrick R.
Insider trading activities of Loscalzo Joseph
Insider trading activities of Jenne Kyle
Insider trading activities of Hayden Michael R
Insider trading activities of Diaz Allene M.
Insider trading activities of Boyce Sarah
Insider trading activities of Schneider Eugene
Insider trading activities of Klein Joseph Iii
Insider trading activities of Birchler Brian
Insider trading activities of Monia Brett P
Insider trading activities of Yang Michael J.
Insider trading activities of Mcdevitt Damien
Insider trading activities of Bennett C Frank
Insider trading activities of Muto Frederick T
Insider trading activities of Cadoret-manier Onaiza
Insider trading activities of Parshall B Lynne
Insider trading activities of Wender Joseph H
Insider trading activities of Hougen Elizabeth L
Insider trading activities of Swayze Eric
Insider trading activities of Berthelsen Spencer R
Insider trading activities of Geary Richard S
Insider trading activities of Baroldi Joseph

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Ionis Pharmaceuticals Inc (IONS).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2025 15,000 $477,900 993,870 $54,623,894 1,107,680 $26,972,189
2024 0 $0 216,854 $10,417,483 306,713 $1,690,800
2023 0 $0 480,350 $22,469,267 633,770 $17,444,961
2022 0 $0 9,319 $373,594 272,987 $291,150
2021 0 $0 128,563 $7,483,627 277,627 $139,500
2020 0 $0 435,149 $22,468,509 430,271 $8,790,881
2019 0 $0 528,804 $37,414,368 631,186 $18,611,478
2018 0 $0 237,729 $11,778,492 331,168 $2,959,654
2017 0 $0 327,296 $17,001,714 394,558 $3,417,846
2016 0 $0 240,936 $9,522,537 302,772 $2,241,037
2015 0 $0 422,957 $27,154,230 458,215 $4,462,683


Table 3. Detailed insider trading at Ionis Pharmaceuticals Inc (IONS) , Part 6
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2016-01-04 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 1,000 9.04 9,035
2016-01-04 Monia Brett P (SVP, Antisense Drug Discovery) Sale 127 61.00 7,747
2016-01-04 Parshall B Lynne (COO & Secretary) Sale 809 61.05 49,389
2016-01-04 Parshall B Lynne (COO & Secretary) Option Ex 809 14.69 11,884
2016-01-04 Crooke Stanley T (Chairman and CEO) Sale 11,000 61.05 671,550
2016-01-04 Crooke Stanley T (Chairman and CEO) Option Ex 11,000 9.76 107,305
2015-12-16 Bennett C Frank (SVP, Antisense Research) Sale 3,909 58.85 230,044
2015-12-16 Bennett C Frank (SVP, Antisense Research) Option Ex 3,909 14.47 56,563
2015-12-15 Bennett C Frank (SVP, Antisense Research) Sale 4,000 56.00 224,000
2015-12-15 Bennett C Frank (SVP, Antisense Research) Option Ex 4,000 14.47 57,880
2015-12-01 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 1,000 61.50 61,500
2015-12-01 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 1,000 7.25 7,250
2015-11-11 Klein Joseph Iii (Director) Sale 6,875 64.18 441,237
2015-11-11 Klein Joseph Iii (Director) Option Ex 6,875 11.12 76,450
2015-11-10 Bennett C Frank (SVP, Antisense Research) Sale 5,000 64.00 320,000
2015-11-10 Bennett C Frank (SVP, Antisense Research) Option Ex 5,000 14.47 72,350
2015-11-06 Bennett C Frank (SVP, Antisense Research) Sale 5,000 56.00 280,000
2015-11-06 Bennett C Frank (SVP, Antisense Research) Option Ex 5,000 14.47 72,350
2015-11-03 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 1,000 51.95 51,950
2015-11-03 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 1,000 7.25 7,250
2015-10-23 Crooke Stanley T (Chairman and CEO) Sale 27,500 44.57 1,225,675
2015-10-23 Crooke Stanley T (Chairman and CEO) Option Ex 27,500 10.06 276,595
2015-10-21 Crooke Stanley T (Chairman and CEO) Sale 16,500 43.00 709,500
2015-10-21 Crooke Stanley T (Chairman and CEO) Option Ex 16,500 10.59 174,685
2015-10-02 Parshall B Lynne (COO & Secretary) Sale 5,436 41.25 224,218
2015-10-02 Parshall B Lynne (COO & Secretary) Option Ex 5,436 14.69 79,854
2015-10-01 Parshall B Lynne (COO & Secretary) Sale 7,000 40.13 280,882
2015-10-01 Parshall B Lynne (COO & Secretary) Option Ex 7,000 10.97 76,790
2015-07-06 Parshall B Lynne (COO & Secretary) Sale 6,218 57.01 354,469
2015-07-06 Parshall B Lynne (COO & Secretary) Option Ex 6,218 8.77 54,531
2015-07-06 Crooke Stanley T (Chairman and CEO) Sale 6,175 57.01 352,018
2015-07-06 Crooke Stanley T (Chairman and CEO) Option Ex 6,175 10.24 63,262
2015-07-02 Monia Brett P (SVP, Antisense Drug Discovery) Sale 198 56.30 11,147
2015-07-02 Klein Joseph Iii (Director) Option Ex 312 .00 0
2015-07-02 Muto Frederick T (Director) Option Ex 312 .00 0
2015-07-02 Berthelsen Spencer R (Director) Option Ex 312 .00 0
2015-07-02 Wender Joseph H (Director) Option Ex 312 .00 0
2015-07-01 Castleman Breaux (Director) Option Ex 2,074 .00 0
2015-07-01 Loscalzo Joseph (Director) Option Ex 667 .00 0
2015-07-01 Klein Joseph Iii (Director) Option Ex 1,136 .00 0
2015-07-01 Muto Frederick T (Director) Option Ex 1,136 .00 0
2015-07-01 Berthelsen Spencer R (Director) Option Ex 1,136 .00 0
2015-07-01 Parshall B Lynne (COO & Secretary) Sale 6,218 57.56 357,914
2015-07-01 Parshall B Lynne (COO & Secretary) Option Ex 6,218 10.29 63,983
2015-07-01 Wender Joseph H (Director) Option Ex 1,136 .00 0
2015-07-01 Crooke Stanley T (Chairman and CEO) Sale 6,175 57.56 355,439
2015-07-01 Crooke Stanley T (Chairman and CEO) Option Ex 6,175 10.24 63,262
2015-06-08 Monia Brett P (SVP, Antisense Drug Discovery) Sale 7,600 66.22 503,279
2015-06-08 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 7,600 10.29 78,204
2015-06-01 Muto Frederick T (Director) Sale 10,000 66.91 669,110
2015-06-01 Muto Frederick T (Director) Option Ex 10,000 3.95 39,500
2015-04-17 Berthelsen Spencer R (Director) Option Ex 10,000 3.95 39,500
2015-04-07 Parshall B Lynne (COO & Secretary) Sale 5,565 63.07 350,990
2015-04-07 Parshall B Lynne (COO & Secretary) Option Ex 5,565 14.69 81,749
2015-04-07 Crooke Stanley T (Chairman and CEO) Sale 22,377 63.07 1,411,339
2015-04-07 Crooke Stanley T (Chairman and CEO) Option Ex 22,377 10.24 229,252
2015-04-01 Parshall B Lynne (COO & Secretary) Sale 5,377 61.93 333,008
2015-04-01 Parshall B Lynne (COO & Secretary) Option Ex 5,377 14.69 78,988
2015-04-01 Crooke Stanley T (Chairman and CEO) Sale 21,623 61.93 1,339,155
2015-04-01 Crooke Stanley T (Chairman and CEO) Option Ex 21,623 10.24 221,527
2015-03-24 Bennett C Frank (SVP, Antisense Research) Sale 9,000 71.01 639,090
2015-03-24 Bennett C Frank (SVP, Antisense Research) Option Ex 9,000 14.47 130,230
2015-03-23 Bennett C Frank (SVP, Antisense Research) Sale 6,000 70.40 422,412
2015-03-23 Bennett C Frank (SVP, Antisense Research) Option Ex 6,000 14.47 86,820
2015-03-19 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 30,525 74.81 2,283,483
2015-03-19 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 30,525 19.82 605,005
2015-03-19 Geary Richard S (SVP, Development) Sale 8,000 75.00 600,032
2015-03-19 Geary Richard S (SVP, Development) Option Ex 8,000 14.69 117,520
2015-03-19 Hougen Elizabeth L (SVP, Finance & CFO) Sale 10,000 73.33 733,259
2015-03-19 Hougen Elizabeth L (SVP, Finance & CFO) Option Ex 10,000 11.27 112,700
2015-03-18 Wender Joseph H (Director) Sale 12,500 71.40 892,450
2015-03-18 Wender Joseph H (Director) Option Ex 12,500 5.93 74,125
2015-03-05 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 5,800 71.67 415,674
2015-03-05 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 5,800 9.14 53,041
2015-03-05 Geary Richard S (SVP, Development) Sale 18,095 71.33 1,290,734
2015-03-05 Geary Richard S (SVP, Development) Option Ex 15,080 9.60 144,813
2015-03-05 Klein Joseph Iii (Director) Sale 7,000 70.95 496,685
2015-03-05 Klein Joseph Iii (Director) Option Ex 10,000 10.49 104,870
2015-03-05 Hougen Elizabeth L (SVP, Finance & CFO) Sale 28,094 71.55 2,010,153
2015-03-05 Hougen Elizabeth L (SVP, Finance & CFO) Option Ex 28,094 9.66 271,303
2015-03-05 Wender Joseph H (Director) Sale 12,500 71.61 895,175
2015-03-05 Wender Joseph H (Director) Option Ex 12,500 9.77 122,125
2015-03-02 Wender Joseph H (Director) Sale 7,000 65.97 461,782
2015-02-12 Wender Joseph H (Director) Sale 10,000 62.15 621,460
2015-02-12 Wender Joseph H (Director) Option Ex 10,000 3.95 39,500
2015-02-03 Loscalzo Joseph (Director) Option Ex 938 .00 0
2015-01-27 Crooke Stanley T (Chairman and CEO) Sale 11,000 72.93 802,186
2015-01-27 Crooke Stanley T (Chairman and CEO) Option Ex 11,000 10.24 112,694
2015-01-16 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 1,291 67.96 87,741
2015-01-16 Monia Brett P (SVP, Antisense Drug Discovery) Sale 1,534 67.96 104,256
2015-01-16 Geary Richard S (SVP, Development) Sale 1,543 67.96 104,868
2015-01-16 Hougen Elizabeth L (SVP, Finance & CFO) Sale 1,291 67.96 87,741
2015-01-16 Bennett C Frank (SVP, Antisense Research) Sale 1,518 67.96 103,169
2015-01-16 Parshall B Lynne (COO & Secretary) Sale 4,093 67.96 278,176
2015-01-16 Crooke Stanley T (Chairman and CEO) Sale 9,054 67.96 615,346
2015-01-15 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 3,383 .00 0
2015-01-15 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 4,025 .00 0
2015-01-15 Geary Richard S (SVP, Development) Option Ex 4,049 .00 0
2015-01-15 Hougen Elizabeth L (SVP, Finance & CFO) Option Ex 3,383 .00 0
2015-01-15 Bennett C Frank (SVP, Antisense Research) Option Ex 3,984 .00 0
2015-01-15 Parshall B Lynne (COO & Secretary) Option Ex 7,748 .00 0
2015-01-15 Crooke Stanley T (Chairman and CEO) Option Ex 17,425 .00 0
2015-01-12 Geary Richard S (SVP, Development) Sale 597 73.10 43,640
2015-01-09 Crooke Stanley T (Chairman and CEO) Sale 11,000 73.57 809,269
2015-01-09 Crooke Stanley T (Chairman and CEO) Option Ex 11,000 10.24 112,694
2015-01-07 Crooke Stanley T (Chairman and CEO) Sale 11,000 68.05 748,528
2015-01-07 Crooke Stanley T (Chairman and CEO) Option Ex 11,000 10.24 112,694
2015-01-06 Crooke Stanley T (Chairman and CEO) Sale 11,000 66.04 726,418
2015-01-06 Crooke Stanley T (Chairman and CEO) Option Ex 11,000 10.24 112,694
2015-01-02 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 1,500 62.12 93,172
2015-01-02 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 1,500 9.04 13,552
2015-01-02 Monia Brett P (SVP, Antisense Drug Discovery) Sale 76 62.75 4,769
2015-01-02 Parshall B Lynne (COO & Secretary) Sale 11,200 62.12 695,688
2015-01-02 Parshall B Lynne (COO & Secretary) Option Ex 11,200 14.69 164,528

Insider trading activities including stock purchases, stock sales, and option exercises of IONS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ionis Pharmaceuticals Inc (symbol IONS, CIK number 874015) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.